Suvannasankha Attaya, Minderman Hans, O'Loughlin Kieran L, Sait Sheila N J, Stewart Carleton C, Greco William R, Baer Maria R
Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Leuk Res. 2004 May;28(5):449-55. doi: 10.1016/j.leukres.2003.09.003.
Acute myeloid leukemia (AML) with rearrangement of the core-binding factor (CBF) alpha or beta subunit gene has a favorable prognosis, but CD56 expression in CBFalpha-AML is associated with short disease-free survival. A proposed mechanism is overexpression of the multidrug resistance (MDR) protein P-glycoprotein (Pgp). CD56 expression, Pgp expression and function, and expression of the additional MDR proteins multidrug resistance protein-1 (MRP-1), lung resistance protein (LRP) and breast cancer resistance protein (BCRP) were studied in pretreatment blasts from 25 CBF-AML patients. CD56 expression was frequent in CBFalpha but rare in CBFbeta, and Pgp expression and function were frequent in both subtypes. CD56 expression did not correlate with Pgp expression or function, nor with expression of the other MDR proteins. Treatment failure associated with CD56 expression in CBFalpha-AML is not likely attributable to Pgp.
伴有核心结合因子（CBF）α或β亚基基因重排的急性髓系白血病（AML）预后良好，但CBFα-AML中的CD56表达与无病生存期短相关。一种提出的机制是多药耐药（MDR）蛋白P-糖蛋白（Pgp）的过表达。对25例CBF-AML患者预处理的原始细胞中CD56表达、Pgp表达及功能，以及其他MDR蛋白多药耐药相关蛋白1（MRP-1）、肺耐药蛋白（LRP）和乳腺癌耐药蛋白（BCRP）的表达进行了研究。CD56表达在CBFα中常见而在CBFβ中少见，Pgp表达及功能在两种亚型中均常见。CD56表达与Pgp表达或功能均不相关, 与其他MDR蛋白的表达也不相关。CBFα-AML中与CD56表达相关的治疗失败不太可能归因于Pgp。
